HC Wainwright reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.
Checkpoint Therapeutics Stock Down 1.2 %
NASDAQ:CKPT opened at $2.43 on Monday. Checkpoint Therapeutics has a 52 week low of $1.30 and a 52 week high of $3.62. The company has a fifty day simple moving average of $2.33 and a two-hundred day simple moving average of $2.03. The company has a market cap of $86.72 million, a price-to-earnings ratio of -0.88 and a beta of 1.29.
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.11. The firm had revenue of $0.04 million for the quarter. On average, analysts expect that Checkpoint Therapeutics will post -0.81 EPS for the current year.
Insider Transactions at Checkpoint Therapeutics
Institutional Trading of Checkpoint Therapeutics
A number of large investors have recently bought and sold shares of CKPT. XTX Topco Ltd purchased a new stake in shares of Checkpoint Therapeutics in the second quarter valued at about $34,000. Lindbrook Capital LLC acquired a new position in Checkpoint Therapeutics in the 1st quarter valued at about $62,000. 180 Wealth Advisors LLC purchased a new stake in Checkpoint Therapeutics during the 2nd quarter valued at approximately $96,000. Choreo LLC lifted its position in Checkpoint Therapeutics by 200.9% during the 1st quarter. Choreo LLC now owns 57,922 shares of the company’s stock worth $119,000 after acquiring an additional 38,672 shares during the period. Finally, PVG Asset Management Corp purchased a new position in shares of Checkpoint Therapeutics in the 2nd quarter valued at approximately $295,000. Institutional investors and hedge funds own 22.00% of the company’s stock.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What is a buyback in stocks? A comprehensive guide for investors
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Stock Analyst Ratings and Canadian Analyst Ratings
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.